Cellectis European patent EP 1 485 475 upheld at European Patent Office
Cellectis CEO André Choulika said, “This decision makes us even more determined in our constant fight to defend our intellectual property rights. Intellectual property is a key value of biotechnology companies and is the launch pad for their growth. Our position means that we are able to invest 80% of our income in very high added value research and development projects.”
To date, Cellectis holds a portfolio of 42 granted patents and more than 130 applications for additional patents pending.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.